Coronary atherosclerotic heart disease
Conditions
Interventions
Test group :Coronary artery stent implantation
Sponsors
Zhengzhou Seventh People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 to 80 years; 2. Patients with coronary artery thrombosis and organization in atherosclerotic lesions, complete occlusion of lumen, and occlusion duration > 3 months; 3. The occluded vessels were located in epicardial coronary artery with reference diameter >= 2.5mm; 4. Patients who comply with all assessments and follow-up protocols.
Exclusion criteria
Exclusion criteria: 1. Patients with acute myocardial infarction in recent 3 months; 2. Patients with rheumatic valvular disease; 3. Patients with severe arrhythmia; 4. Not suitable for patients with PCI lesions; 5. Patients with severe hematopoietic system abnormalities, such as platelet count 700 * 10^9 / L, white blood cell count < 3 * 10^9 / L; 6. Patients with active bleeding or bleeding tendency (active ulcer, short-term ischemic stroke, history of hemorrhagic stroke, intracranial space occupying lesions, recent craniocerebral trauma and other bleeding or bleeding tendency); 7. Patients with severe coexisting diseases, including severe renal insufficiency [glomerular filtration rate less than 60 ml / min 1.73 M2], severe liver insufficiency [upper limit of normal reference value of glutamic pyruvate transaminase (ALT) or glutamic aldehyde acetic transaminase (ALT) increased more than three times], severe heart failure (NYHA III-V), acute infectious diseases and immune diseases; Tumor; The operation was performed within 3 months; 8. Patients with life expectancy less than 12 months; 9. Pregnant or planned pregnant subjects; 10. Patients with allergic or adverse reactions to aspirin, clopidogrel, ticagrel, pigment, contrast agent, anticoagulant or stent; 11. Patients who could not tolerate dual antiplatelet therapy; 12. Patients who are unable to communicate due to cognitive impairment, hearing or visual impairment; 13. Subjects who participate in another drug or device trial that has not yet reached the primary endpoint, or plan to participate in the clinical trial within 12 months after the intervention.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Late lumen loss;Myocardial markers;proBNP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Target vessel reconstruction;Major Cardiovascular and Cerebrovascular Adverse Events ; | — |
Countries
China
Contacts
Public ContactTao Hu
Xijing Hospital of the Fourth Military Medical University of the Chinese people's Liberation Army
Outcome results
None listed